The relevance of the active MEK/ERK pathway in cancer stem-like cells with tumor initiating properties is demonstrated by the significant delay in tumor development (11.4 vs 18.1 weeks) and reduced tumor size displayed by xeno-transplanted RD cells pre-cultured in the presence of the MEK/ERK inhibitor. Here, MAP2K7 is linked to cancer.